Bharat Immunological Biological Corporation Ltd vs Corona Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.3 as of 06 May 15:30 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd is 0 as of March 2023 .The P/E Ratio of Corona Remedies Ltd is 0 as of March 2023 . The Market Cap of Bharat Immunological & Biological Corporation Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Corona Remedies Ltd is ₹ 0 crore as of March 2023 . The revenue of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Corona Remedies Ltd for the Dec '25 is ₹ 344.68 crore as compare to the Sep '25 revenue of ₹ 363.57 crore. This represent the decline of -5.2% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Corona Remedies Ltd for the Dec '25 is ₹ 66.32 crore as compare to the Sep '25 ebitda of ₹ 80.91 crore. This represent the decline of -18.03% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Corona Remedies Ltd changed from ₹ 29.95 crore to ₹ 41.27 crore over 7 quarters. This represents a CAGR of 20.11% The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Corona Remedies Ltd changed from 20 % on March 2023 to 30 % on March 2025 . This represents a CAGR of 14.47% over 3 years .

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Corona Remedies Ltd

Corona Remedies Limited was originally incorporated as CORONA Remedies Private Limited', a private limited company, dated August 27, 2004, issued by the Assistant Registrar of Companies, Gujarat at Dadra and Nagar Haveli.
Thereafter, Company converted into a public limited and Company name has changed to CORONA Remedies Limited'.
A fresh certificate of incorporation, is issued by the Registrar of Companies, Central Processing Centre, Manesar, Haryana on December 16, 2024. The manufacturing facilities of the Company are located at Solan (Himachal Pradesh) and at Bhayla (Ahmedabad, Gujarat).
The Company is engaged in manufacturing, trading and marketing of Pharmaceutical products in women's healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. In 2004, Company launched the first division, and later named it as Pioneer' division in year 2010; launched Xemx (multispeciality) division in 2005.

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Corona Remedies Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Corona Remedies Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 74 Cr while Market cap of Corona Remedies Ltd is 10,682 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Corona Remedies Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Corona Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Corona Remedies Ltd?

As of May 6, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.3. On the other hand, Corona Remedies Ltd stock price is INR ₹1746.6.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Corona Remedies Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Corona Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.